Lilly Scores Twice, Boehringer Ingelheim Once At EMA
This article was originally published in The Pink Sheet Daily
Executive Summary
Boehringer Ingelheim’s Vargatef and Eli Lilly’s Cyramza, both cancer drugs, got the nod from EMA this month, while Lilly also received a thumbs-up for its Trulicity diabetes therapy.